Although anti-TNF agents such as adalimumab play an important role in the management of IBD, primary non-response to anti-TNFs occurs in 10–40% of patients.4 Identifying factors that predict response to anti-TNF therapy may improve the success of the treat-to-target approach recommended in IBD management guidelines.5,6. The gene discussed is TNF; the disease is inflammatory bowel disease.